{"transactions":[{"id":1100242,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-06-27T16:18:21.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":554681,"derivative":{"exercise_price":5.5,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001826667-25-000083","document":"wk-form4_1751055493.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000182666725000083/wk-form4_1751055493.xml","form_type":"4"}},{"id":1139023,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-21T17:28:57.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":44884,"price":5.18,"value":232499.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The granted RSUs vest immediately."}],"balance_after":123989,"source":{"system":"sec-edgar","filing":"0001826667-25-000055","document":"wk-form4_1747862929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000182666725000055/wk-form4_1747862929.xml","form_type":"4"}},{"id":1259989,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Manuf, Strategy&Bus Dev."}}],"security":"Common Stock","published_at":"2025-02-19T17:54:19.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":15817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 12.5% of the shares subject to the RSU Award shall vest on the grant date of February 18, 2025; 25% of the shares subject to the RSU Award shall vest on each of May 15, 2025, August 15, 2025, and November 14, 2025; and the remaining shares subject to the RSU Award will vest on February 13, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":79105,"source":{"system":"sec-edgar","filing":"0001415889-25-004691","document":"form4-02192025_100215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588925004691/form4-02192025_100215.xml","form_type":"4"}},{"id":1291834,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Manuf, Strategy&Bus Dev."}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-29T18:13:10.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025 (the \"VCD\"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":5.3,"expiration_date":"2035-01-26","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-25-002291","document":"form4-01292025_110106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588925002291/form4-01292025_110106.xml","form_type":"4"}},{"id":1291833,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Manuf, Strategy&Bus Dev."}}],"security":"Common Stock","published_at":"2025-01-29T18:13:10.000Z","date":"2025-01-28","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":5.17,"value":77550.0,"ownership":{"direct":false,"nature":"By Sean E Murphy TTEE U/A 2/4/2004"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.94 to $5.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":197732,"source":{"system":"sec-edgar","filing":"0001415889-25-002291","document":"form4-01292025_110106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588925002291/form4-01292025_110106.xml","form_type":"4"}},{"id":1291832,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Manuf, Strategy&Bus Dev."}}],"security":"Common Stock","published_at":"2025-01-29T18:13:10.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":5.31,"value":79650.0,"ownership":{"direct":false,"nature":"By Sean E Murphy TTEE U/A 2/4/2004"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.09 to $5.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":182732,"source":{"system":"sec-edgar","filing":"0001415889-25-002291","document":"form4-01292025_110106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588925002291/form4-01292025_110106.xml","form_type":"4"}},{"id":1291831,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Manuf, Strategy&Bus Dev."}}],"security":"Common Stock","published_at":"2025-01-29T18:13:10.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on January 1, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":63288,"source":{"system":"sec-edgar","filing":"0001415889-25-002291","document":"form4-01292025_110106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588925002291/form4-01292025_110106.xml","form_type":"4"}},{"id":1643188,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-14T18:17:05.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":105000,"derivative":{"exercise_price":9.5,"expiration_date":"2034-02-11","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001415889-24-003806","document":"form4-02142024_110255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588924003806/form4-02142024_110255.xml","form_type":"4"}},{"id":1643187,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-14T18:17:05.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":34144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":50788,"source":{"system":"sec-edgar","filing":"0001415889-24-003806","document":"form4-02142024_110255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588924003806/form4-02142024_110255.xml","form_type":"4"}},{"id":1670941,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-25T17:46:59.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of January 24, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":125000,"derivative":{"exercise_price":9.28,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-24-001820","document":"form4-01252024_100149.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000141588924001820/form4-01252024_100149.xml","form_type":"4"}},{"id":1808610,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-14T19:21:32.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":62500,"derivative":{"exercise_price":12,"expiration_date":"2033-08-10","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001209191-23-045730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919123045730/doc4.xml","form_type":"4"}},{"id":2185658,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-15T16:14:07.000Z","date":"2022-08-15","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":3.6,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":6.4,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-028633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000089924322028633/doc4.xml","form_type":"4"}},{"id":2185657,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T16:14:07.000Z","date":"2022-08-15","kind":"other","acquired":false,"shares":5500,"price":10,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000089924322028633/doc4.xml","form_type":"4"}},{"id":2426731,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-25T16:30:42.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":6.4,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-004786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919122004786/doc4.xml","form_type":"4"}},{"id":2426730,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-25T16:30:42.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001209191-22-004786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919122004786/doc4.xml","form_type":"4"}},{"id":2839522,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-23T17:58:04.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":18.6,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-013347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919121013347/doc4.xml","form_type":"4"}},{"id":2839521,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-23T17:58:04.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001209191-21-013347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919121013347/doc4.xml","form_type":"4"}},{"id":2897735,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-25T17:13:04.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the first anniversary of the grant date or upon an earlier Change of Control (as defined in the registrant's 2018 Stock Option and Incentive Plan)."}],"balance_after":20000,"derivative":{"exercise_price":22,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-005129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919121005129/doc4.xml","form_type":"4"}},{"id":3060363,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-12T16:33:28.000Z","date":"2020-08-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in substantially equal installments on each of the first four anniversaries of August 10, 2020."}],"balance_after":30000,"derivative":{"exercise_price":12.61,"expiration_date":"2030-08-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-046375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120046375/doc4.xml","form_type":"4"}},{"id":3082763,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":392927,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":315098},"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082762,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":860585,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":690124},"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082761,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":1457725,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1168985},"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082760,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":8746356,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7013918},"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082759,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"purchase","acquired":true,"shares":10000,"price":16,"value":160000.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082758,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":315098,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":9188125,"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082757,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":690124,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":8873027,"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082756,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":1168985,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":8182903,"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3082755,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-15T17:00:16.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":7013918,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc (\"Malin\"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":7013918,"source":{"system":"sec-edgar","filing":"0001209191-20-042500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042500/doc4.xml","form_type":"4"}},{"id":3084385,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-13T19:00:09.000Z","date":"2020-07-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":16,"expiration_date":"2030-07-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-042312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919120042312/doc4.xml","form_type":"4"}},{"id":3901738,"issuer":{"id":111882,"kind":"organization","name":"Novan, Inc.","symbol":"NOVN"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-07T20:53:41.000Z","date":"2018-06-04","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal quarterly installments, with the first installment vesting on September 4, 2018."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2028-06-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-036553","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919118036553/doc4.xml","form_type":"4"}},{"id":4289952,"issuer":{"id":111882,"kind":"organization","name":"Novan, Inc.","symbol":"NOVN"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-07T18:03:56.000Z","date":"2017-06-05","kind":"grant","acquired":true,"shares":34014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal quarterly installments, with the first installment vesting on September 5, 2017."}],"balance_after":34014,"derivative":{"exercise_price":4.64,"expiration_date":"2027-06-04","underlying":"Common Stock","underlying_shares":34014},"source":{"system":"sec-edgar","filing":"0001209191-17-038402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000120919117038402/doc4.xml","form_type":"4"}},{"id":4597219,"issuer":{"id":111882,"kind":"organization","name":"Novan, Inc.","symbol":"NOVN"},"owners":[{"id":78045,"kind":"person","name":"Murphy Sean","position":1,"cik":"0001685042","reported_name":"Murphy Sean","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2016-09-22T16:46:54.000Z","date":"2016-09-20","kind":"grant","acquired":true,"shares":14484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal quarterly installments, with the first installment vesting on December 20, 2016."}],"balance_after":14484,"derivative":{"exercise_price":11,"expiration_date":"2026-09-19","underlying":"Common Stock","underlying_shares":14484},"source":{"system":"sec-edgar","filing":"0000899243-16-029753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685042/000089924316029753/doc4.xml","form_type":"4"}}]}